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Summary. Research on Parkinson's disease has led to new hypotheses 
concerning the mechanisms of neurodegeneration and to the development 
of neuroprotective agents. Recent findings of impaired mitochondrial func-
tion, altered iron metabolism and increased lipid peroxidation in the sub-
stantia nigra of parkinsonian patients emphasize the significance of oxidative 
stress and free radical formation in the pathogenesis of Parkinson's disease. 
Present research is therefore focussing on improvements in neuroprotective 
therapy to prevent or slow the rate of progression of the disease. Possible 
neuroprotective strategies include free radical scavengers, monoamine 
oxidase-B inhibitors, iron chelators and glutamate antagonists. 
Recent studies point to the possibility of achieving neuroprotection in 
ageing and parkinsonism by the administration of dopamine agonists. In the 
rat, the dopamine agonist pergolide appears to preserve the integrity of 
nigrostriatal neurones with ageing. The prevention of age-related degenera-
tion may be achieved as a result of a decreased dopamine turnover and 
reduced conversion of dopamine to toxic compounds. In our own study, 
bromocriptine treatment prevented the striatal dopamine reduction follow-
ing MPTP administration in the mouse. These results suggest that the 
neurotoxic effects of MPTP can be prevented by bromocriptine. Mono-
therapy with the dopamine agonist lisuride in the early stages of Parkinson's 
disease delays the need for the initiation of levodopa treatment to a similar 
extent as has been reported for L-deprenyl. It remains to be shown whether 
this is due to neuroprotective efficacy of the dopamine agonist or to a direct 
symptomatic effect. 
Introduction 
The most important neuropathological feature of Parkinson's disease is the 
loss of catecholaminergic neurones in the brainstem (German et al., 1989; 
Jellinger, 1991). The degeneration of the melanin-pigmented dopaminergic 
neurones of the substantia nigra pars compacta is the pathological basis of 
the movement disorders characterizing Parkinson's disease. The cause 
of degeneration of dopamine-containing neurones in Parkinson's disease 
remains unknown. The finding that dopamine levels are reduced in the 
striatum and substantia nigra of parkinsonian subjects (Ehringer and 
Hornykiewicz, 1960) has led to the introduction of replacement therapies 
including L - D O P A (Birkmayer and Hornykiewicz, 1961), dopamine full 
(Calne et al., 1974; LeWitt, 1986; Sage and Duvoisin, 1985) and partial 
agonists (Lange et al., 1992b), and of the monoamine oxidase type B 
(MAO-B) inhibitor L-deprenyl (Birkmayer et al., 1975). 
The selective vulnerability of the nigrostriatal dopamine-containing 
neurones to the toxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine 
(MPTP) and the striking resemblance of the resulting clinical syndrome to 
Parkinson's disease has focussed research activity on the search for aeti-
ological factors that may contribute to the development of Parkinson's 
disease. 
Pathogenesis of Parkinson's disease 
The discovery that the neurotoxin MPTP induces neuropathological and 
neurochemical alterations as well as clinical signs very similar to those of 
Parkinson's disease (Ballard et al., 1985; Burns et al., 1985) suggests that 
there are neurotoxic compounds in the environment similar to MPTP. 
Although there is some epidemiological evidence in support of a role 
of environmental neurotoxins (Snyder and D'Amato, 1986; Tanner and 
Langston, 1990; Riederer and Lange, 1992), no such toxic agent has been 
identified. Even if MPTP and related substances are not the cause of 
Parkinson's disease, MPTP neurotoxicity provides clues as to the mechanism 
underlying neuronal death in this disease. 
The discovery of a defect in mitochondrial electron transport at complex 
I in the substantia nigra of parkinsonian patients (Schapira et al., 1990) has 
led to the hypothesis that a mitochondrial abnormality can increase the 
vulnerability of some individuals to neurodegeneration involving the sub-
stantia nigra. The complex I deficiency may be caused by an MPTP-like 
substance or may be determined genetically. Putative mitochondrial 
abnormalities may not be the primary aetiological factor but could be 
secondary to another metabolic deficit, e.g. excess free radicals produced 
from other sources than complex I inhibition may cause the complex I 
deficiency reported in Parkinson's disease. 
It has been suggested that oxidative stress or excess free radical formation 
play a role in the pathogenesis of Parkinson's disease (Graham et al., 1978; 
Spina and Cohen, 1989; Youdim et al., 1990). There are two theoretical 
concepts of how oxidation reactions and toxic oxygen species may contribute 
to the degenerative process underlying neuronal death in Parkinson's 
disease. 
The first concept proposes that excess formation of free radicals occurs as 
a result of toxin action. The neurotoxin MPTP expresses its toxicity as a 
consequence of its oxidation to the l-methyl-4-phenyl-pyridinium ion 
( M P P + ) by monoamine oxidase type B (MAO-B) (Chiba et al., 1984; Salach 
et al., 1984; Heikkila et al., 1985). Inhibition of the oxidation of MPTP to 
M P P + by M A O - B inhibitors such as deprenyl and pargyline prevents the 
neurotoxic effects of MPTP and the development of a parkinsonian syn-
drome in animal models of Parkinson's disease (Cohen et al., 1984; Heikkila 
et al., 1984; Langston et al., 1984b). If Parkinson's disease is caused by 
MPTP-like compounds, oxidation reactions may be essential for the de-
velopment of Parkinson's disease. The toxic effects of M P P + are thought to 
be caused by its ability to inhibit complex I of the mitochondrial respiratory 
chain (Nicklas et al., 1985; Vyas et al., 1986) resulting in decreased cellular 
adenosine triphosphate levels (DiMonte et al., 1986) and altered intracellular 
calcium content (Kass et al., 1988). Alterations in the homoeostasis of 
intracellular calcium are closely linked with altered cell function and cell 
death (Orrenius et al., 1989). Recent studies have shown that the calcium 
binding protein calbindin is selectively decreased in the substantia nigra in 
Parkinson's disease (Iacopino and Christakos, 1990). The inhibition of 
mitochondrial function may also lead to increased formation of free radical 
species. 
The second concept concerning the importance of oxidation reactions 
and free radical formation in the pathogenesis of Parkinson's disease relates 
to the metabolism of dopamine. Several lines of evidence suggest that 
dopamine or products of dopamine metabolism are neurotoxic. It has been 
shown, for example, that dopamine depletion has a protective effect on 
ischaemia-induced striatal damage. Brain anoxia causes a release of large 
quantities of dopamine in the gerbil (Brannan et al., 1987). In the rat, the 
unilateral destruction of the nigrostriatal dopaminergic pathway by 6-
hydroxydopamine protects striatal neurones on the ipsilateral side against 
damage from global forebrain ischaemia (Globus et al., 1987a,b; Clemens 
and Phebus, 1988). The hypothesis of a neurotoxic role of dopamine 
is supported by the finding that dopamine depletion by alpha-methylpara-
tyrosine protects the dopamine re-uptake mechanism of striatal nerve 
endings against destruction by ischaemia (Weinberger et al., 1985). These 
results suggest that, at least in cerebral ischaemia, dopamine is involved in 
the process leading to neuronal cell death. 
Several neurochemical characteristics of the substantia nigra may 
enhance free radical formation and contribute to oxidative stress vul-
nerability. Dopamine can be oxidatively metabolized by the enzyme 
monoamine oxidase (MAO) . The polymerization of auto-oxidative products 
of dopamine leads to the formation of neuromelanin and the characteristic 
pigmentation of the substantia nigra. Both auto-oxidation of dopamine 
and oxidative deamination by M A O result in the formation of hydrogen 
peroxide ( H 2 0 2 ) . Under normal circumstances H 2 0 2 is rather inert and 
never accumulates in the brain or other organs. H 2 0 2 is normally cleared 
from the brain by the glutathione system. Glutathione peroxidase catalyzes 
the reaction of H 2 0 2 with glutathione (GSH) to form glutathione disulfide 
(GSSG): 
Glutathione 
peroxidase 
H 2 0 2 + 2GSH > 2 H 2 0 + GSSG 
In the presence of iron, H 2 0 2 can be reduced to form the toxic hydroxyl 
free radical (Fenton reaction): 
H 2 0 2 + F e 2 + > O H + O H " + F e 3 + 
M A O activity in the brain increases with ageing (Fowler et al., 1980) and 
this may lead to an increase in the formation of H 2 0 2 which could exceed 
the capacity of the glutathione system. Similarly, a reduction in glutathione 
or glutathione peroxidase could prevent the clearance of H 2 0 2 generated 
from normal dopamine metabolism (Sofic et al., 1992). The result of either 
of these mechanisms could be the insufficient clearance of H 2 0 2 and the 
production of hydroxyl free radicals which may cause damage to dopamine-
containing cells. 
Within the brain, high concentrations of iron have been shown to exist 
in the substantia nigra and striatum (Hill and Switzer, 1984; Riederer et al., 
1989). Free tissue metals such as F e 2 + can initiate the formation of cytotoxic 
oxygen free radicals resulting from their interaction with hydrogen peroxide. 
This leads to promotion of membrane lipid peroxides. A selective increase 
in iron content occurs in the substantia nigra in Parkinson's disease 
(Riederer et al., 1989; Dexter et al., 1989; Jellinger et al., 1990; Sofic et al., 
1991). Melanin-iron interaction leads to a potentiation of iron-induced basal 
lipid peroxidation (Ben-Shachar and Youdim, 1990). These findings suggest 
that oxidative stress induced by iron-melanin interaction is a possible 
mechanism in the aetiology of Parkinson's disease without involving an 
endogenously or exogenously derived neurotoxin (Youdim et al., 1989). 
Table 1. Evidence supporting a state of oxidative stress in the substantia nigra in 
Parkinson's disease 
Disturbed mitochondrial respiratory function with reduction in complex I and III 
activities 
Altered cellular calcium homoeostasis with decrease in calcium-binding protein 
Decreased glutathione and glutathione peroxidase activity leading to a reduced ability 
to scavenge hydrogen peroxide derived from oxidative deamination and auto-oxidation 
of dopamine 
Increased iron content resulting in a potential excess of radical-generating free iron 
Increased mitochondrial superoxide dismutase activity, perhaps reflecting an attempt 
to compensate for oxidative stress 
Increased peroxidation of membrane lipids inducing membrane damage and cell death 
Recent research on the biochemical pathology of Parkinson's disease 
indicates that free radicals generated from oxidation reactions play an 
important role in the neuronal loss in the substantia nigra in Parkinson's 
disease (for review see Lange et al., 1992a, and Table 1). 
Neuroprotective strategies in Parkinson's disease 
The biochemical alterations in Parkinson's disease such as increased lipid 
peroxidation, altered iron metabolism and impairment of mitochondrial 
function point to oxidative stress as an important factor contributing to 
neuronal loss in the substantia nigra in Parkinson's disease. Protection 
against such oxidative damage could be provided by scavengers of free 
radicals and anti-oxidants such as M A O - B inhibitors, alpha-tocopherol 
(vitamin E) , ascorbic acid (vitamin C), glutathione and iron chelators (see 
Table 2). 
Treatment with ascorbic acid in the mouse has been reported to reverse 
the decrease in striatal dopamine levels caused by the systemic administra-
tion of MPTP or focal injection of M P P + into the striatum (Sershen et al., 
1985; Wagner et al., 1985, 1986). Alpha-tocopherol has been shown to 
prevent nigral cell loss in MPTP-treated mice (Perry et al., 1985) and has 
been reported in an open-label study to retard the clinical progression of 
Parkinson's disease in therapeutically naive patients (Fahn, 1989). Another 
open study showed that parkinsonian patients taking alpha-tocopherol had 
less severe deficits than those not taking the substance (Factor et al., 1990). 
The D A T A T O P study has compared the effect of alpha-tocopherol and 
placebo on disease progression in a prospective, double-blind trial and has 
found that tocopherol produced no beneficial effects (Parkinson Study 
Group, 1989, 1993). 
The findings of a selective increase in oxidative stress and in F e 3 + 
content in the substantia nigra in Parkinson's disease suggest that iron 
chelators may be able to prevent the retardation of the dopaminergic 
neurodegeneration. The dopaminergic neurotoxic effect of 6-hydroxy-
dopamine is thought to involve the generation of oxygen free radicals 
(Heikkila and Cohen, 1972; Sachs and Jonsson, 1975; Graham et al., 1978) 
presumably initiated by a transitional metal. The administration of the iron 
chelator desferoxamine in the rat protects against the 6-hydroxydopamine-
induced reduction in striatal dopamine content and the development of 
dopamine-related behavioural changes (Ben-Shachar et al., 1991). The 
ability of iron chelators to retard dopaminergic neurodegeneration in the 
substantia nigra may point to a new neuroprotective approach in Parkinson's 
disease. Iron chelators such as amino steroids have shown protective activity 
in animal models of trauma and ischaemia and are able to cross the blood-
brain barrier and to inhibit iron-dependent lipid peroxidation (Braughler et 
al., 1987; Hall , 1988; Hall and Yonkers, 1988). 
The selective M A O - B inhibitor L-deprenyl was initially employed as an 
adjunct to L - D O P A , based on the hypothesis that inhibition of dopamine 
metabolism would increase dopamine availability. M A O - B inhibitors in-
crease brain levels of dopamine and phenylethylamine (Neff et al., 1974; 
Riederer et al., 1984) and L-deprenyl potentiates the anti-parkinsonian 
action of L - D O P A (Birkmayer et al., 1975; Elizan et al., 1991). Retrospec-
tive studies showed that patients who received both L - D O P A and L-
deprenyl lived longer than patients who were treated with L - D O P A alone 
(Birkmayer et al., 1985). Two randomized, prospective, double-blind studies 
have compared L-deprenyl with placebo in otherwise untreated subjects 
with early Parkinson's disease (Parkinson Study Group, 1989, 1993; Tetrud 
and Langston, 1989). Both studies demonstrated that L-deprenyl produced 
a prolongation of the period before systematic therapy was required. L-
deprenyl appears to delay the onset of disability and to have a neuroprotec-
tive effect by slowing the rate of progression of Parkinson's disease in newly 
diagnosed patients. 
L-deprenyl may decrease the generation of hydrogen peroxide associated 
with dopamine catabolism through its action as an M A O - B inhibitor and 
slow the progression of Parkinson's disease by reducing the death of sub-
stantia nigra neurones induced by endogenous neurotoxic free radicals. A 
neuroprotective role of L-deprenyl has been demonstrated in the mouse. L-
Deprenyl reduced oxidative stress associated with an increased turnover of 
dopamine induced by haloperidol and limited the accumulation of GSSG in 
the striatum (Cohen and Spina, 1989). 
The hypothesis of neuroprotective efficacy of L-deprenyl has been 
questioned recently (Landau, 1990; Ward, 1994), since the reduced pro-
bability of reaching the endpoint, i.e. the decision to treat with levo-
dopa, may have been due to a direct treatment effect rather than to 
neuroprotection. 
The inhibition of MPTP-induced neurotoxicity by L-deprenyl given prior 
to the toxin is well established. It has recently been shown that L-deprenyl 
increases the survival of substantia nigra neurones in the mouse even when 
the drug is administered days following the MPTP treatment (Tatton and 
Greenwood, 1991). This finding suggests a neuroprotective mechanism that 
is independent of M A O - B activity. It can rather be related to the stimulation 
of neurotrophic factors or regenerative processes than to M A O - B activity. 
Neuroprotective activity may be a generalized feature of both M A O - A 
and M A O - B inhibitors. The selective reversible M A O - A inhibitor moclobe-
mide (p-chloro-N-[2-morpholinoethyl]benzamide) has been reported to have 
neuroprotective effects due to the inhibition of generation of hydrogen 
peroxide via M A O - A reactions (Da Prada et al., 1990). 
There is evidence indicating that excitatory amino acids are involved in 
the neurotoxic effects of MPTP. Systemic administration of MPTP to 
humans and non-human primates causes parkinsonian motor deficits asso-
ciated with a selective destruction of dopamine-containing neurones in the 
substantia nigra pars compacta and a marked reduction in striatal dopamine 
content (Davis et al., 1979; Langston et al., 1983, 1984a; Burns et al., 
1983). Neurotoxicity appears to be due to the formation of l-methyl-4-
phenylpyridinium ion (MPP + ) (Castagnoli et al., 1985; Sanchez-Ramos et 
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Table 2. Neuroprotective strategies in Parkinson's disease 
Biochemical alterations in the substantia nigra Possible neuroprotective therapies 
Formation of hydrogen peroxide 
Increased iron content 
Formation of toxic oxygen free radicals 
Alteration in the homoeostasis of intracellular 
calcium 
Increased dopamine turnover 
Excess activity of excitatory amino acids (?) 
MAO-B inhibitors 
Iron chelators 
Free radical scavengers 
Calcium entry blockers 
Dopamine agonists 
Excitatory amino acid antagonists 
al., 1988; Lange, 1990) which is the result of the conversion of MPTP by 
M A O - B into the dihydropyridinium species ( M P D P + ) which is converted 
non-enzymatically into M P P + . This compound is subsequently transported 
by the dopamine uptake process to accumulate within dopaminergic 
neurones and to be temporarily stored in a releasable pool (Javitch et al., 
1985; Schinelli et al., 1988). The toxicity of M P P + apparently occurs as the 
result of intraneuronal uptake by a mitochondrial carrier and inhibition of 
complex I of the mitochondrial respiratory chain (Nicklas et al., 1985). 
Excitatory amino acids such as glutamate appear to be involved in the 
pathophysiological cascade of MPTP/MPP + -induced neuronal death. It has 
been shown that M P P + causes a release of glutamate and aspartate in the 
rat brain (Carboni et al., 1990). Gutamate antagonists, which competitively 
or non-competitively block the N M D A subtype of receptor, protect dopa-
minergic nigral neurones against destruction by M P P * injected directly into 
the substantia nigra pars compacta (SNC) of rats (Turski et al., 1991). Since 
rats are less sensitive to M P P + than primates, the doses of the toxin needed 
to produce brain damage are very high and could cause unspecific toxic 
effects (Harik et al., 1987). In the mouse, the non-competitive N M D A -
receptor antagonist (+)-5-methyl-10, ll-dihydro-5H-dibenzo[a,d]cyclo-
hepten-5,10-imine maleate (MK-801) has been shown to be ineffective in 
preventing the dopamine depletion induced by systemic administration of 
MPTP (Sonsalla et al., 1989, 1992). Recent studies in monkeys, however, 
have demonstrated that glutamate antagonists are able to modulate the 
neurotoxicity of MPTP. The competitive N M D A antagonist 3-((±)-2-
carboxypiperazin-4-yl)-propyl-l-phosphonic acid (CPP) protects tyrosine 
hydroxylase (TH)-positive neurones in the substantia nigra from degenera-
tion induced by systemic treatment with MPTP in the common marmoset 
(Lange et al., 1993). The non-competitive N M D A antagonist MK-801 
prevents the development of the parkinsonian syndrome in the cynomolgus 
monkey (Zuddas et al., 1992) and protects nigral tyrosine hydroxylase-
positive neurones in cynomolgus monkeys (Zuddas et al., 1992) and 
marmosets (Lange et al., unpublished observation) from degeneration 
following the administration of MPTP. 
The neuroprotective action of competitive and non-competitive N M D A 
receptor antagonists against MPTP toxicity supports the hypothesis that 
N M D A receptor-mediated events are involved in the neurotoxicity of 
MPTP and M P P + . M P P + interferes with mitochondrial respiration and 
depletes cell energy resources (Nicklas et al., 1985). Neuronal energy 
deprivation could alter the normal functioning of cell membranes and cause 
a partial depolarization leading to a release of the voltage dependent M g 2 + 
block of N M D A receptor ion channels (Nowak et al., 1984). Removal of 
the M g 2 + block enables excitatory amino acids to excite their receptors 
persistently, to open the ion channels and to become neurotoxic (Novelli et 
al., 1988). 
Pergolide and ageing 
As has been described above, dopamine can play a neurotoxic role in 
ischaemic brain damage. Recent studies have addressed the question 
of whether dopamine may be involved in the age-related decline of the 
dopaminergic nigrostriatal system and the destruction of dopamine-
containing neurones. This hypothesis can be tested by a chronic reduction 
of dopamine synthesis and release over the entire life-span of an animal. 
This can be achieved by a continuous stimulation of the dopamine auto-
receptors causing a decrease in dopamine availability. Pergolide is not only 
a potent dopamine agonist at postsynaptic dopamine receptors but also a 
potent agonist at presynaptic dopamine autoreceptors (Fuller et al., 1982). 
This compound is not subject to auto-oxidation and the production of toxic 
reactive oxygen intermediates. 
The effects of dietary administration of pergolide for two years on 
alterations of the nigrostriatal system have been observed in the rat (Felten 
et al., 1992). Fischer-344 rats were fed a diet containing 0.001% of pergolide 
from three months of age until the age of 26 months. A control group was 
pair-fed with the pergolide group in order to control for food consumption 
and body weight. Some animals were killed at 18 months of age, i.e. after 
15 months of continuous pergolide administration. In comparison to control 
animals, rats on pergolide treatment for 15 months showed a reduced 
dopamine turnover in the striatum as expressed by markedly lower levels of 
3,4-dihydroxyphenylacetic acid (DOPAC) . At 26 months of age both the 
pergolide group and the pair-fed control group were killed and compared 
with a group of young rats aged three months. The density of cell bodies in 
the substantia nigra pars compacta, determined with fluorescence his-
tochemistry, was reduced in the 26-month-old pair-fed control rats when 
compared with both 26-month-old pergolide-treated group and the 3-
month-old control group. The relative density of cell bodies in the substantia 
nigra of the rats treated with pergolide did not differ from that of the young 
control rats aged three months (Felten et al., 1992). The density of dopamine 
terminals in the rostral striatum of the pergolide-treated group did not differ 
from the 3-month-old control group. The 26-month-old pair-fed control 
group, however, showed a clearly reduced density of striatal dopamine 
terminals. These results suggest that chronic pergolide administration is able 
to preserve the integrity of the dopaminergic nigrostriatal system during 
ageing. There was no difference in tissue content of dopamine and D O P A C 
when 3-month-old control rats and 26-month-old pergolide-treated and pair-
fed animals were compared (Felten et al., 1992). Since the number of 
dopaminergic neurones was reduced in the pair-fed group, each neuron 
must have synthesized more dopamine to compensate. In the neurochemical 
analyses the total tissue content of dopamine was measured whereas in 
the histochemical fluorescence studies only intracellular dopamine was 
determined and extracellular dopamine did not contribute to the fluo-
rescence. The dopaminergic neurones in old animals therefore seem to 
produce more dopamine to compensate for the loss of neurones. 
In the rat pergolide appears to preserve the integrity of nigrostriatal 
neurones with ageing. The prevention of age-related degeneration may be 
the result of a decreased dopamine turnover and reduced conversion 
of dopamine to toxic compounds. Pergolide has been shown to induce 
superoxide dismutase in the rat striatum (Clow et al., 1992). This effect may 
help to protect against nigrostriatal degeneration. 
Bromocriptine and MPTP neurotoxicity 
The MPTP animal model offers the opportunity to investigate possible 
neuroprotective effects of compounds in an experimental parkinsonian 
syndrome. We have tested whether the dopamine agonist bromocriptine can 
influence the neurotoxicity of MPTP in the mouse. 
Male C57/B16 mice (Charles River, Sulzfeld, Germany) weighing 18-
20 g were used. They were housed under standard laboratory conditions 
(12h light, 12h darkness, food pellets and tap water ad libitum). 
One group of mice (n = 17) received bromocriptine (lOOmg/kg) dissolved 
in 0.2ml of 5% gum arabic solution through a pharyngeal tube twice 
daily for 3 days (treatment schedule see Table 3). Sixty minutes later 
diethyldithiocarbamate (400mg/kg, Sigma) dissolved in 0.2 ml saline was 
injected intraperitoneally. Thirty minutes following the D D C administra-
Table 3. Treatment schedule for C57/B16 mice 
Time 7.30 8.30 9.00 19.30 20.30 21.00 
Day 1 
Day 2 
Day 3 
Day 7 
B R O M O 
B R O M O 
B R O M O 
Decapitation 
DDC 
DDC 
DDC 
MPTP 
MPTP 
MPTP 
B R O M O 
BROMO 
BROMO 
DDC 
DDC 
DDC 
MPTP 
MPTP 
MPTP 
BROMO bromocriptine (lOOmg/kg); DDC diethyldithiocarbamate (400mg/kg); MPTP 
l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (12mg/kg) 
tion, MPTP hydrochloride (12mg/kg, Paesel, Austria) dissolved in 0.2ml 
saline was injected i.p. 
Another group of mice (n = 19) was treated with D D C and MPTP 
according to the above treatment schedule and received vehicle instead of 
bromocriptine. A third group (n - 4) was treated with bromocriptine only 
and injected with vehicle instead of D D C and MPTP. The final control 
group (n = 30) did not receive any active compound but was injected with 
vehicle according to the same time schedule as the other three groups. 
Six days following the first treatment all animals were decapitated. The 
brains were immediately removed and the cortex, striatum and substantia 
nigra were dissected. The brain tissue samples were stored at — 80°C until 
further processing. For neurotransmitter analysis tissue samples (2-20 mg) 
were homogenized with a sonicator in 0.2 ml of 0.4 M HC10 4 for 30 seconds, 
the homogenates were then centrifuged at 3,000 x g for 5 minutes. The 
supernatant was dissolved in 1ml of 1 M Tris buffer (pH 8.66), 800 pg 
Dopamine: ug/g 
12 
Vehicle BROMO DDC+MPTP DDC+MPTP 
• B R O M O 
Noradrenaline: ug/g 
0.3-
Vehicle BROMO DDC+MPTP DDC+MPTP 
• B R O M O 
Fig. 1. Dopamine and noradrenaline levels (mean ± S.D.) in the striatum of mice 
treated with vehicle, bromocriptine (lOOmg/kg twice daily for 3 days), DDC (400mg/kg 
twice daily for 3 days) plus MPTP (12mg/kg twice daily for 3 days) or bromocriptine 
plus DDC plus MPTP. tp < 0.01 for comparison with vehicle group, *p < 0.01 for 
comparison with DDC+MPTP group (Welch t-test) 
of 3,4-dihydroxybenzylamine-HBr ( D H B A ) were added as an internal 
standard. The catecholamines were extracted in 50 mg of acid-washed 
alumina (Merck) by shaking for 15 minutes. The supernatant was aspirated 
and the alumina was washed with 1ml of 0 .1M Tris buffer and then with 
1ml of distilled water. The bound catecholamines were dissolved with 
0.2 ml of 0.4 HC10 4 . Following centrifugation at 12,000 x g, 25^1 were 
injected into an H P L C system consisting of an H P L C pump (ESA-5700, 
Bedford, U . S . A . ; E S A catecholamine HR-80 column, length 80mm, 3|im 
spherical octadecylsilane) and an electrochemical detector (ESA-5100A; 
potentials for guard cell 0.10 V , detector 1 0.35 V , detector 2 0.20 V) . The 
solvent used was Cat-A-Phase (ESA). Dopamine and noradrenaline were 
separated at a flow of 1 ml/min according to the method described by Sofic 
(1986). Catecholamine levels in the brain regions examined were compared 
using the Welch t-test. 
In comparison with the animals treated with vehicle, the administration 
of D D C plus MPTP caused a decrease of dopamine in the striatum of about 
Dopamine: gg/g 
0.3 
0.2 
0.1 
Vehicle BROMO DDC+MPTP DDC+MPTP 
+ BROMO 
Noradrenaline: gg/g 
Vehicle BROMO DDC+MPTP DDC+MPTP 
+ BROMO 
Fig. 2. Dopamine and noradrenaline levels (mean ± S.D.) in the substantia nigra of 
mice treated with vehicle, bromocriptine (lOOmg/kg twice daily for 3 days), DDC 
(400mg/kg twice daily for 3 days) plus MPTP (12mg/kg twice daily for 3 days) or 
bromocriptine plus D D C plus MPTP. tp < 0.01 for comparison with vehicle group, 
*p < 0.01 for comparison with DDC+MPTP group (Welch t-test) 
70% (see Fig. 1). Treatment with D D C , MPTP and bromocriptine was 
associated with striatal dopamine levels that were higher than those in the 
D D C plus MPTP group and comparable to those in the control groups 
treated with vehicle or bromocriptine alone (see Fig. 1). Striatal noradrena-
line levels did not differ between the experimental and control groups. 
Dopamine content in the substantia nigra was not significantly reduced 
following D D C plus MPTP compared to the vehicle group (see Fig. 2). 
Treatment with D D C plus MPTP plus bromocriptine, however, caused 
higher dopamine levels than the administration of D D C and MPTP (Fig. 2). 
Apart from an increase in noradrenaline following bromocriptine in com-
parison with vehicle administration, there were no differences between the 
treatment groups. Cortical dopamine and noradrenaline levels were reduced 
following the treatment with D D C and MPTP in comparison with the 
vehicle control group (see Fig. 3). 
The administration of D D C and MPTP in mice caused a decrease in 
dopamine content in the striatum and cortex. Additional treatment with 
0.1 
0.08 
0.06 
0.04 
0.02 j 
Dopamine: ug/g 
i ! 
Vehicle BROMO DDC+MPTP DDC+MPTP 
+ BROMO 
Noradrenaline: ug/g 
0.4 
Vehicle BROMO DDC+MPTP DDC+MPTP 
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Fig. 3. Dopamine and noradrenaline levels (mean ± S.D.) in the cortex of mice 
treated with vehicle, bromocriptine (lOOmg/kg twice daily for 3 days), DDC (400mg/kg 
twice daily for 3 days) plus MPTP (12mg/kg twice daily for 3 days) or bromocriptine 
plus DDC plus MPTP. tp < 0.01 for comparison with vehicle group (Welch t-test) 
bromocriptine prevented the dopamine reduction in the striatum and pro-
duced higher dopamine levels in the substantia nigra than following D D C 
plus MPTP. These results suggest that the neurotoxic effects of MPTP in 
the mouse can be prevented by bromocriptine. At present it is not clear 
how dopamine agonists such as bromocriptine protect dopaminergic neu-
rones against the neurotoxic effects of MPTP. The neuroprotective effect of 
bromocriptine could be brought about by a reduction in dopamine turnover 
and dopamine uptake and a reduced uptake of MPTP into dopamine-
containing neurones. Dopamine agonists may also play a role as free 
radical scavengers. Further studies should address the question of whether 
bromocriptine has neuroprotective efficacy in parkinsonian patients. 
Dopamine agonists in Parkinson's disease 
In a retrospective analysis, the effects of lisuride monotherapy on the need 
for levodopa therapy has been investigated (Runge and Horowski, 1991). 
The clinical observations in 185 parkinsonian patients treated with lisuride 
alone showed a significant lengthening of the period before levodopa therapy 
was needed. The initiation of levodopa administration could be postponed 
for a year or longer in about 60% of patients. After several years most 
patients required levodopa as an additional or alternative treatment. About 
10% of the patients showed satisfactory efficacy of lisuride monotherapy for 
more than five years. The clinical results with lisuride monotherapy (Runge 
and Horowski, 1991) were comparable to those obtained with L-deprenyl 
in the D A T A T O P study (Parkinson Study Group, 1989). Symptomatic 
therapy with the dopamine agonist lisuride in early Parkinson's disease is 
able to postpone the need for levodopa therapy to a similar extent as has 
been reported for the M A O - B inhibitor L-deprenyl. In two preliminary 
notes, the absence of observable clinical progression of Parkinson's disease 
has been reported for patients receiving pergolide for up to seven years in 
addition to levodopa therapy (Lichter et al., 1988; Zimmerman and Sage, 
1991). 
The results concerning lisuride and pergolide in Parkinson's disease 
need confirmation by prospective studies. If dopamine agonists slow the 
progression of Parkinson's disease, this may be caused by the stimulation of 
the presynaptic autoreceptor and the reduction of the dopamine and free 
radical load on the nigrostriatal system. This may be true for patients in the 
early stages without levodopa therapy. However, in parkinsonian subjects 
taking high doses of levodopa, it would seem impossible that the adminis-
tration of dopamine agonists could decrease the free radical load to a 
sufficient extent. 
The question that remains to be answered is whether delaying the need 
for levodopa therapy is a suitable parameter for the evaluation of the 
progression of the disease and therefore of a possible neuroprotective 
efficacy of a drug, since there is no evidence showing that lisuride acts on 
the neurodegenerative process directly. In the case of L-deprenyl, a favour-
able effect on the progression of Parkinson's disease has been postulated 
(Parkinson Study Group, 1989, 1993). 
A major argument against the neuroprotective action of L-deprenyl in 
the trial of the Parkinson Study Group (1989) has been the short wash-out 
period of one month. It has been argued that the symptomatic effects of the 
drug may still have been apparent (Landau, 1990). However, an increase in 
the concentration of amines is observed only following M A O inhibition of 
about 80% (Green and Youdim, 1976). Therefore, the symptomatic effect 
of an M A O inhibitor is lost relatively rapidly as the enzyme recovers from 
total blockade. New protein synthesis to levels of enzyme protein that 
sufficiently metabolize the amine takes place in rats within the first two 
weeks, in monkeys within four weeks and in humans within an unknown 
period following cessation of an irreversible M A O inhibitor. However, 
urinary phenylethylamine concentrations, which increase 20 to 90-fold 
following L-deprenyl administration, drop to normal excretion levels within 
a few days following L-deprenyl withdrawal (Elsworth et al., 1978). Never-
theless the design of the L-deprenyl study (Parkinson Study Group, 1989, 
1993) has been questioned with regard to the assessment of neuroprotective 
properties of the drug. 
With regard to the possible neuroprotection by dopamine agonists in 
Parkinson's disease, a clear distinction between neuroprotective and sym-
ptomatic effects could be made only by the administration of a dopamine 
agonist without any effects on the parkinsonian symptoms (Lange and 
Riederer, 1994b). 
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